The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Castration Resistant Prostate Cancer Treatment Market Research Report 2025
Synopsis
Prostate cancer can be defined as it is a form of cancer that develops into male reproductive system. Most of the prostate cancer are slow growing and stable but sometimes it can spread from prostate (gland) to other part of body such as bone and lymph node. Initially prostate cancer does not pose any symptom but in severe cases it can cause pain during urination and can cause problem during sexual intercourse. Castration resistant prostate cancer is referred to as a prostate cancer that is spread to other parts of body and is resistant to medical or surgical treatment. Risk factor for castration resistant prostate cancer includes genetic predisposition, geriatric population, unhygienic diet, medication exposure and many sexual partners. Diagnosis for the detection of castration resistant prostate cancer includes prostate imaging, biopsy, tumor marker and staging test. Crucial factor about castration resistant prostate cancer is that it is resistant to medical and surgical treatment. However, other treatment options that are available in the market include hormone therapy, immune modulation, antiangiogenic treatment and bone targeted therapies.
The global Castration Resistant Prostate Cancer Treatment market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Castration Resistant Prostate Cancer Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Castration Resistant Prostate Cancer Treatment.
Report Scope
The Castration Resistant Prostate Cancer Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Castration Resistant Prostate Cancer Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Castration Resistant Prostate Cancer Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Active Biotech
Diagnocure
Glaxosmithkline
Northwest Biotherapeutics
Millennium Pharmaceuticals
Hologic
Spectrum Pharmaceuticals
Abbott Laboratories
Bayer Healthcare Pharmaceuticals
Segment by Type
Hormonal Therapy
Adding An Anti-Androgen
Stopping An Anti-Androgen
Estrogens
Chemotherapy
Radiation Therapy
Others
Segment by Application
Hospital
Ambulatory Surgical Centers
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Castration Resistant Prostate Cancer Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Prostate cancer can be defined as it is a form of cancer that develops into male reproductive system. Most of the prostate cancer are slow growing and stable but sometimes it can spread from prostate (gland) to other part of body such as bone and lymph node. Initially prostate cancer does not pose any symptom but in severe cases it can cause pain during urination and can cause problem during sexual intercourse. Castration resistant prostate cancer is referred to as a prostate cancer that is spread to other parts of body and is resistant to medical or surgical treatment. Risk factor for castration resistant prostate cancer includes genetic predisposition, geriatric population, unhygienic diet, medication exposure and many sexual partners. Diagnosis for the detection of castration resistant prostate cancer includes prostate imaging, biopsy, tumor marker and staging test. Crucial factor about castration resistant prostate cancer is that it is resistant to medical and surgical treatment. However, other treatment options that are available in the market include hormone therapy, immune modulation, antiangiogenic treatment and bone targeted therapies.
The global Castration Resistant Prostate Cancer Treatment market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Castration Resistant Prostate Cancer Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Castration Resistant Prostate Cancer Treatment.
Report Scope
The Castration Resistant Prostate Cancer Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Castration Resistant Prostate Cancer Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Castration Resistant Prostate Cancer Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Active Biotech
Diagnocure
Glaxosmithkline
Northwest Biotherapeutics
Millennium Pharmaceuticals
Hologic
Spectrum Pharmaceuticals
Abbott Laboratories
Bayer Healthcare Pharmaceuticals
Segment by Type
Hormonal Therapy
Adding An Anti-Androgen
Stopping An Anti-Androgen
Estrogens
Chemotherapy
Radiation Therapy
Others
Segment by Application
Hospital
Ambulatory Surgical Centers
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Castration Resistant Prostate Cancer Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Castration Resistant Prostate Cancer Treatment Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Hormonal Therapy
1.2.3 Adding An Anti-Androgen
1.2.4 Stopping An Anti-Androgen
1.2.5 Estrogens
1.2.6 Chemotherapy
1.2.7 Radiation Therapy
1.2.8 Others
1.3 Market by Application
1.3.1 Global Castration Resistant Prostate Cancer Treatment Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Ambulatory Surgical Centers
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Castration Resistant Prostate Cancer Treatment Market Perspective (2019-2030)
2.2 Castration Resistant Prostate Cancer Treatment Growth Trends by Region
2.2.1 Global Castration Resistant Prostate Cancer Treatment Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Castration Resistant Prostate Cancer Treatment Historic Market Size by Region (2019-2024)
2.2.3 Castration Resistant Prostate Cancer Treatment Forecasted Market Size by Region (2025-2030)
2.3 Castration Resistant Prostate Cancer Treatment Market Dynamics
2.3.1 Castration Resistant Prostate Cancer Treatment Industry Trends
2.3.2 Castration Resistant Prostate Cancer Treatment Market Drivers
2.3.3 Castration Resistant Prostate Cancer Treatment Market Challenges
2.3.4 Castration Resistant Prostate Cancer Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Castration Resistant Prostate Cancer Treatment Players by Revenue
3.1.1 Global Top Castration Resistant Prostate Cancer Treatment Players by Revenue (2019-2024)
3.1.2 Global Castration Resistant Prostate Cancer Treatment Revenue Market Share by Players (2019-2024)
3.2 Global Castration Resistant Prostate Cancer Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Castration Resistant Prostate Cancer Treatment Revenue
3.4 Global Castration Resistant Prostate Cancer Treatment Market Concentration Ratio
3.4.1 Global Castration Resistant Prostate Cancer Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Castration Resistant Prostate Cancer Treatment Revenue in 2023
3.5 Castration Resistant Prostate Cancer Treatment Key Players Head office and Area Served
3.6 Key Players Castration Resistant Prostate Cancer Treatment Product Solution and Service
3.7 Date of Enter into Castration Resistant Prostate Cancer Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Castration Resistant Prostate Cancer Treatment Breakdown Data by Type
4.1 Global Castration Resistant Prostate Cancer Treatment Historic Market Size by Type (2019-2024)
4.2 Global Castration Resistant Prostate Cancer Treatment Forecasted Market Size by Type (2025-2030)
5 Castration Resistant Prostate Cancer Treatment Breakdown Data by Application
5.1 Global Castration Resistant Prostate Cancer Treatment Historic Market Size by Application (2019-2024)
5.2 Global Castration Resistant Prostate Cancer Treatment Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Castration Resistant Prostate Cancer Treatment Market Size (2019-2030)
6.2 North America Castration Resistant Prostate Cancer Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Castration Resistant Prostate Cancer Treatment Market Size by Country (2019-2024)
6.4 North America Castration Resistant Prostate Cancer Treatment Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Castration Resistant Prostate Cancer Treatment Market Size (2019-2030)
7.2 Europe Castration Resistant Prostate Cancer Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Castration Resistant Prostate Cancer Treatment Market Size by Country (2019-2024)
7.4 Europe Castration Resistant Prostate Cancer Treatment Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Castration Resistant Prostate Cancer Treatment Market Size (2019-2030)
8.2 Asia-Pacific Castration Resistant Prostate Cancer Treatment Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Castration Resistant Prostate Cancer Treatment Market Size by Region (2019-2024)
8.4 Asia-Pacific Castration Resistant Prostate Cancer Treatment Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Castration Resistant Prostate Cancer Treatment Market Size (2019-2030)
9.2 Latin America Castration Resistant Prostate Cancer Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Castration Resistant Prostate Cancer Treatment Market Size by Country (2019-2024)
9.4 Latin America Castration Resistant Prostate Cancer Treatment Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Castration Resistant Prostate Cancer Treatment Market Size (2019-2030)
10.2 Middle East & Africa Castration Resistant Prostate Cancer Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Castration Resistant Prostate Cancer Treatment Market Size by Country (2019-2024)
10.4 Middle East & Africa Castration Resistant Prostate Cancer Treatment Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Active Biotech
11.1.1 Active Biotech Company Detail
11.1.2 Active Biotech Business Overview
11.1.3 Active Biotech Castration Resistant Prostate Cancer Treatment Introduction
11.1.4 Active Biotech Revenue in Castration Resistant Prostate Cancer Treatment Business (2019-2024)
11.1.5 Active Biotech Recent Development
11.2 Diagnocure
11.2.1 Diagnocure Company Detail
11.2.2 Diagnocure Business Overview
11.2.3 Diagnocure Castration Resistant Prostate Cancer Treatment Introduction
11.2.4 Diagnocure Revenue in Castration Resistant Prostate Cancer Treatment Business (2019-2024)
11.2.5 Diagnocure Recent Development
11.3 Glaxosmithkline
11.3.1 Glaxosmithkline Company Detail
11.3.2 Glaxosmithkline Business Overview
11.3.3 Glaxosmithkline Castration Resistant Prostate Cancer Treatment Introduction
11.3.4 Glaxosmithkline Revenue in Castration Resistant Prostate Cancer Treatment Business (2019-2024)
11.3.5 Glaxosmithkline Recent Development
11.4 Northwest Biotherapeutics
11.4.1 Northwest Biotherapeutics Company Detail
11.4.2 Northwest Biotherapeutics Business Overview
11.4.3 Northwest Biotherapeutics Castration Resistant Prostate Cancer Treatment Introduction
11.4.4 Northwest Biotherapeutics Revenue in Castration Resistant Prostate Cancer Treatment Business (2019-2024)
11.4.5 Northwest Biotherapeutics Recent Development
11.5 Millennium Pharmaceuticals
11.5.1 Millennium Pharmaceuticals Company Detail
11.5.2 Millennium Pharmaceuticals Business Overview
11.5.3 Millennium Pharmaceuticals Castration Resistant Prostate Cancer Treatment Introduction
11.5.4 Millennium Pharmaceuticals Revenue in Castration Resistant Prostate Cancer Treatment Business (2019-2024)
11.5.5 Millennium Pharmaceuticals Recent Development
11.6 Hologic
11.6.1 Hologic Company Detail
11.6.2 Hologic Business Overview
11.6.3 Hologic Castration Resistant Prostate Cancer Treatment Introduction
11.6.4 Hologic Revenue in Castration Resistant Prostate Cancer Treatment Business (2019-2024)
11.6.5 Hologic Recent Development
11.7 Spectrum Pharmaceuticals
11.7.1 Spectrum Pharmaceuticals Company Detail
11.7.2 Spectrum Pharmaceuticals Business Overview
11.7.3 Spectrum Pharmaceuticals Castration Resistant Prostate Cancer Treatment Introduction
11.7.4 Spectrum Pharmaceuticals Revenue in Castration Resistant Prostate Cancer Treatment Business (2019-2024)
11.7.5 Spectrum Pharmaceuticals Recent Development
11.8 Abbott Laboratories
11.8.1 Abbott Laboratories Company Detail
11.8.2 Abbott Laboratories Business Overview
11.8.3 Abbott Laboratories Castration Resistant Prostate Cancer Treatment Introduction
11.8.4 Abbott Laboratories Revenue in Castration Resistant Prostate Cancer Treatment Business (2019-2024)
11.8.5 Abbott Laboratories Recent Development
11.9 Bayer Healthcare Pharmaceuticals
11.9.1 Bayer Healthcare Pharmaceuticals Company Detail
11.9.2 Bayer Healthcare Pharmaceuticals Business Overview
11.9.3 Bayer Healthcare Pharmaceuticals Castration Resistant Prostate Cancer Treatment Introduction
11.9.4 Bayer Healthcare Pharmaceuticals Revenue in Castration Resistant Prostate Cancer Treatment Business (2019-2024)
11.9.5 Bayer Healthcare Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Castration Resistant Prostate Cancer Treatment Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Hormonal Therapy
Table 3. Key Players of Adding An Anti-Androgen
Table 4. Key Players of Stopping An Anti-Androgen
Table 5. Key Players of Estrogens
Table 6. Key Players of Chemotherapy
Table 7. Key Players of Radiation Therapy
Table 8. Key Players of Others
Table 9. Global Castration Resistant Prostate Cancer Treatment Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 10. Global Castration Resistant Prostate Cancer Treatment Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 11. Global Castration Resistant Prostate Cancer Treatment Market Size by Region (2019-2024) & (US$ Million)
Table 12. Global Castration Resistant Prostate Cancer Treatment Market Share by Region (2019-2024)
Table 13. Global Castration Resistant Prostate Cancer Treatment Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 14. Global Castration Resistant Prostate Cancer Treatment Market Share by Region (2025-2030)
Table 15. Castration Resistant Prostate Cancer Treatment Market Trends
Table 16. Castration Resistant Prostate Cancer Treatment Market Drivers
Table 17. Castration Resistant Prostate Cancer Treatment Market Challenges
Table 18. Castration Resistant Prostate Cancer Treatment Market Restraints
Table 19. Global Castration Resistant Prostate Cancer Treatment Revenue by Players (2019-2024) & (US$ Million)
Table 20. Global Castration Resistant Prostate Cancer Treatment Market Share by Players (2019-2024)
Table 21. Global Top Castration Resistant Prostate Cancer Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Castration Resistant Prostate Cancer Treatment as of 2023)
Table 22. Ranking of Global Top Castration Resistant Prostate Cancer Treatment Companies by Revenue (US$ Million) in 2023
Table 23. Global 5 Largest Players Market Share by Castration Resistant Prostate Cancer Treatment Revenue (CR5 and HHI) & (2019-2024)
Table 24. Key Players Headquarters and Area Served
Table 25. Key Players Castration Resistant Prostate Cancer Treatment Product Solution and Service
Table 26. Date of Enter into Castration Resistant Prostate Cancer Treatment Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Castration Resistant Prostate Cancer Treatment Market Size by Type (2019-2024) & (US$ Million)
Table 29. Global Castration Resistant Prostate Cancer Treatment Revenue Market Share by Type (2019-2024)
Table 30. Global Castration Resistant Prostate Cancer Treatment Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 31. Global Castration Resistant Prostate Cancer Treatment Revenue Market Share by Type (2025-2030)
Table 32. Global Castration Resistant Prostate Cancer Treatment Market Size by Application (2019-2024) & (US$ Million)
Table 33. Global Castration Resistant Prostate Cancer Treatment Revenue Market Share by Application (2019-2024)
Table 34. Global Castration Resistant Prostate Cancer Treatment Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 35. Global Castration Resistant Prostate Cancer Treatment Revenue Market Share by Application (2025-2030)
Table 36. North America Castration Resistant Prostate Cancer Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 37. North America Castration Resistant Prostate Cancer Treatment Market Size by Country (2019-2024) & (US$ Million)
Table 38. North America Castration Resistant Prostate Cancer Treatment Market Size by Country (2025-2030) & (US$ Million)
Table 39. Europe Castration Resistant Prostate Cancer Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 40. Europe Castration Resistant Prostate Cancer Treatment Market Size by Country (2019-2024) & (US$ Million)
Table 41. Europe Castration Resistant Prostate Cancer Treatment Market Size by Country (2025-2030) & (US$ Million)
Table 42. Asia-Pacific Castration Resistant Prostate Cancer Treatment Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 43. Asia-Pacific Castration Resistant Prostate Cancer Treatment Market Size by Region (2019-2024) & (US$ Million)
Table 44. Asia-Pacific Castration Resistant Prostate Cancer Treatment Market Size by Region (2025-2030) & (US$ Million)
Table 45. Latin America Castration Resistant Prostate Cancer Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 46. Latin America Castration Resistant Prostate Cancer Treatment Market Size by Country (2019-2024) & (US$ Million)
Table 47. Latin America Castration Resistant Prostate Cancer Treatment Market Size by Country (2025-2030) & (US$ Million)
Table 48. Middle East & Africa Castration Resistant Prostate Cancer Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 49. Middle East & Africa Castration Resistant Prostate Cancer Treatment Market Size by Country (2019-2024) & (US$ Million)
Table 50. Middle East & Africa Castration Resistant Prostate Cancer Treatment Market Size by Country (2025-2030) & (US$ Million)
Table 51. Active Biotech Company Detail
Table 52. Active Biotech Business Overview
Table 53. Active Biotech Castration Resistant Prostate Cancer Treatment Product
Table 54. Active Biotech Revenue in Castration Resistant Prostate Cancer Treatment Business (2019-2024) & (US$ Million)
Table 55. Active Biotech Recent Development
Table 56. Diagnocure Company Detail
Table 57. Diagnocure Business Overview
Table 58. Diagnocure Castration Resistant Prostate Cancer Treatment Product
Table 59. Diagnocure Revenue in Castration Resistant Prostate Cancer Treatment Business (2019-2024) & (US$ Million)
Table 60. Diagnocure Recent Development
Table 61. Glaxosmithkline Company Detail
Table 62. Glaxosmithkline Business Overview
Table 63. Glaxosmithkline Castration Resistant Prostate Cancer Treatment Product
Table 64. Glaxosmithkline Revenue in Castration Resistant Prostate Cancer Treatment Business (2019-2024) & (US$ Million)
Table 65. Glaxosmithkline Recent Development
Table 66. Northwest Biotherapeutics Company Detail
Table 67. Northwest Biotherapeutics Business Overview
Table 68. Northwest Biotherapeutics Castration Resistant Prostate Cancer Treatment Product
Table 69. Northwest Biotherapeutics Revenue in Castration Resistant Prostate Cancer Treatment Business (2019-2024) & (US$ Million)
Table 70. Northwest Biotherapeutics Recent Development
Table 71. Millennium Pharmaceuticals Company Detail
Table 72. Millennium Pharmaceuticals Business Overview
Table 73. Millennium Pharmaceuticals Castration Resistant Prostate Cancer Treatment Product
Table 74. Millennium Pharmaceuticals Revenue in Castration Resistant Prostate Cancer Treatment Business (2019-2024) & (US$ Million)
Table 75. Millennium Pharmaceuticals Recent Development
Table 76. Hologic Company Detail
Table 77. Hologic Business Overview
Table 78. Hologic Castration Resistant Prostate Cancer Treatment Product
Table 79. Hologic Revenue in Castration Resistant Prostate Cancer Treatment Business (2019-2024) & (US$ Million)
Table 80. Hologic Recent Development
Table 81. Spectrum Pharmaceuticals Company Detail
Table 82. Spectrum Pharmaceuticals Business Overview
Table 83. Spectrum Pharmaceuticals Castration Resistant Prostate Cancer Treatment Product
Table 84. Spectrum Pharmaceuticals Revenue in Castration Resistant Prostate Cancer Treatment Business (2019-2024) & (US$ Million)
Table 85. Spectrum Pharmaceuticals Recent Development
Table 86. Abbott Laboratories Company Detail
Table 87. Abbott Laboratories Business Overview
Table 88. Abbott Laboratories Castration Resistant Prostate Cancer Treatment Product
Table 89. Abbott Laboratories Revenue in Castration Resistant Prostate Cancer Treatment Business (2019-2024) & (US$ Million)
Table 90. Abbott Laboratories Recent Development
Table 91. Bayer Healthcare Pharmaceuticals Company Detail
Table 92. Bayer Healthcare Pharmaceuticals Business Overview
Table 93. Bayer Healthcare Pharmaceuticals Castration Resistant Prostate Cancer Treatment Product
Table 94. Bayer Healthcare Pharmaceuticals Revenue in Castration Resistant Prostate Cancer Treatment Business (2019-2024) & (US$ Million)
Table 95. Bayer Healthcare Pharmaceuticals Recent Development
Table 96. Research Programs/Design for This Report
Table 97. Key Data Information from Secondary Sources
Table 98. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Castration Resistant Prostate Cancer Treatment Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Castration Resistant Prostate Cancer Treatment Market Share by Type: 2023 VS 2030
Figure 3. Hormonal Therapy Features
Figure 4. Adding An Anti-Androgen Features
Figure 5. Stopping An Anti-Androgen Features
Figure 6. Estrogens Features
Figure 7. Chemotherapy Features
Figure 8. Radiation Therapy Features
Figure 9. Others Features
Figure 10. Global Castration Resistant Prostate Cancer Treatment Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 11. Global Castration Resistant Prostate Cancer Treatment Market Share by Application: 2023 VS 2030
Figure 12. Hospital Case Studies
Figure 13. Ambulatory Surgical Centers Case Studies
Figure 14. Castration Resistant Prostate Cancer Treatment Report Years Considered
Figure 15. Global Castration Resistant Prostate Cancer Treatment Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 16. Global Castration Resistant Prostate Cancer Treatment Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 17. Global Castration Resistant Prostate Cancer Treatment Market Share by Region: 2023 VS 2030
Figure 18. Global Castration Resistant Prostate Cancer Treatment Market Share by Players in 2023
Figure 19. Global Top Castration Resistant Prostate Cancer Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Castration Resistant Prostate Cancer Treatment as of 2023)
Figure 20. The Top 10 and 5 Players Market Share by Castration Resistant Prostate Cancer Treatment Revenue in 2023
Figure 21. North America Castration Resistant Prostate Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. North America Castration Resistant Prostate Cancer Treatment Market Share by Country (2019-2030)
Figure 23. United States Castration Resistant Prostate Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Canada Castration Resistant Prostate Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Europe Castration Resistant Prostate Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Europe Castration Resistant Prostate Cancer Treatment Market Share by Country (2019-2030)
Figure 27. Germany Castration Resistant Prostate Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. France Castration Resistant Prostate Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. U.K. Castration Resistant Prostate Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Italy Castration Resistant Prostate Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Russia Castration Resistant Prostate Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Nordic Countries Castration Resistant Prostate Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Asia-Pacific Castration Resistant Prostate Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Asia-Pacific Castration Resistant Prostate Cancer Treatment Market Share by Region (2019-2030)
Figure 35. China Castration Resistant Prostate Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Japan Castration Resistant Prostate Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. South Korea Castration Resistant Prostate Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Southeast Asia Castration Resistant Prostate Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. India Castration Resistant Prostate Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Australia Castration Resistant Prostate Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Latin America Castration Resistant Prostate Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Latin America Castration Resistant Prostate Cancer Treatment Market Share by Country (2019-2030)
Figure 43. Mexico Castration Resistant Prostate Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Brazil Castration Resistant Prostate Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Middle East & Africa Castration Resistant Prostate Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Middle East & Africa Castration Resistant Prostate Cancer Treatment Market Share by Country (2019-2030)
Figure 47. Turkey Castration Resistant Prostate Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. Saudi Arabia Castration Resistant Prostate Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 49. Active Biotech Revenue Growth Rate in Castration Resistant Prostate Cancer Treatment Business (2019-2024)
Figure 50. Diagnocure Revenue Growth Rate in Castration Resistant Prostate Cancer Treatment Business (2019-2024)
Figure 51. Glaxosmithkline Revenue Growth Rate in Castration Resistant Prostate Cancer Treatment Business (2019-2024)
Figure 52. Northwest Biotherapeutics Revenue Growth Rate in Castration Resistant Prostate Cancer Treatment Business (2019-2024)
Figure 53. Millennium Pharmaceuticals Revenue Growth Rate in Castration Resistant Prostate Cancer Treatment Business (2019-2024)
Figure 54. Hologic Revenue Growth Rate in Castration Resistant Prostate Cancer Treatment Business (2019-2024)
Figure 55. Spectrum Pharmaceuticals Revenue Growth Rate in Castration Resistant Prostate Cancer Treatment Business (2019-2024)
Figure 56. Abbott Laboratories Revenue Growth Rate in Castration Resistant Prostate Cancer Treatment Business (2019-2024)
Figure 57. Bayer Healthcare Pharmaceuticals Revenue Growth Rate in Castration Resistant Prostate Cancer Treatment Business (2019-2024)
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
